培美曲塞维持治疗晚期非小细胞肺癌临床疗效的Meta分析

doi:10.11904/j.issn.1002-3070.2016.01.006

Abstract

Abstract: Objective This paper aims to assess the clinical efficacy of pemetrexed maintenance therapy in patients with advanced non-small cell lung cancer(NSCLC)through Meta analysis.Methods Systematic literature searches were performed in Cochrane、Pubmed,Web of science,Embase and ClinicalTrials databases.The related references had been traced.We made quality assessment of qualified randomized controlled trials(RCTs)of pemetrexed maintenance therapy compared with best supportive care(BSC)in advanced NSCLC.Besides,we utilized stata 12.0,Revman 5.3 and GRADEpro software to evaluate the overall quality of the evidence,according to the Cochrane collaboration to perform Meta-analysis.Results Three RCTs were eligible and included 1257 patients.Meta-analysis Results suggested that:compared to BSC,pemetrexed maintenance therapy had a statistically significant benefit in improving progression-free survival(PFS)(HR = 0.55,95% CI:0.48~0.64)and overall survival(HR=0.76,95%CI:0.65~0.88).The Objective response(ORR)did not reach statistical significance(RR=0.97,95%CI:0.86~1.10).Conclusion Compared with BSC,pemetrexed maintenance therapy statistically significantly improve PFS and OS,but has no demonstrable impact on ORR in patients with advanced NSCLC.

Key words: Pemetrexed, Non-small cell lung cancer, Maintenance therapy, Meta-analysis

CLC Number:

R734.2

CHENG Long, ZHOU Jianguo, ZHOU Hang. Maintenance therapy with pemetrexed for advanced non-small cell lung cancer:A Meta-analysis of RCTs[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 28-35.

References

1 Siegel R,Ma J,Zou Z,et al.Cancer statistics,2014[J].CA Cancer J Clin,2014,64(1):9-29.
2 Chen W,Zheng R,Zeng H,et al.Annual report on status of cancer in China[J],2011,Chin J Cancer Res,2015,27(1):2-12.
3 Pfister DG,Johnson DH,Azzoli CG,et al.American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline:Update 2003[J].J Clin Oncol,2004,22(2):330-353.
4 Izzedine H.Pemetrexed nephrotoxicity[J].Bull Cancer,2015,102(2):190-197.
5 周建国,周权,马虎.EpiData软件在定量系统评价数据提取中的应用[J].循证医学,2014,14(6):361-363.
6 Mubarak N,Gaafar R,Shehata S,et al.A randomized,phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced,non-squamous,non-small cell lung cancer[J].BMC Cancer,2012,12(423):1407-2407.
7 Ciuleanu T,Brodowicz T,Zielinski C,et al.Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer:a randomised,double-blind,phase 3 study[J].Lancet,2009,374(9699):1432-1440.
8 Paz-Ares L,de Marinis F,Dediu M,et al.Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer(PARAMOUNT):a double-blind,phase 3,randomised controlled trial[J].The Lancet Oncology,2012,13(3):247-255.
9 Paz-Ares LG,de Marinis F,Dediu M,et al.PARAMOUNT:Final overall survival results of the phase Ⅲ study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer[J].J Clin Oncol,2014,31(23):2895-2902.
10 Genova C,Rijavec E,Truini A,et al,Pemetrexed for the treatment of non-small cell lung cancer[J].Expert Opin Pharmacother,2013,14(11):1545-1558.
11 Baldwin CM,Perry CM.Pemetrexed:a review of its use in the management of advanced non-squamous non-small cell lung cancer[J].Drugs,2009,69(16):2279-2302.
12 Belani CP,Wu YL,Chen YM,et al.Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from east Asia with advanced,nonsquamous non-small cell lung cancer[J].Journal of Thoracic Oncology,2012,7(3):567-573.
13 Shi Y,Sun Y.Medical management of lung cancer:Experience in China[J].Thorac Cancer,2015,6(1):10-16.
14 Balshem H,Helfanda M,Schunemann HJ,et al.GRADE指南证据质量分级[J].中国循证医学杂志,2011,11(4):451-455.

[1]	WANG Yalong, LYU Zhangyan, ZHANG Fan, FENG Xiaoshuang, WEI Luopei, LI Xin, WEN Yan, GAO Yushun, XUE Qi, GAO Shugeng, TAN Fengwei. Relationship between human papillomavirus infection and prognosis of lung cancer:A meta-analysis [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 520-526.
[2]	LI Wanzhen, YIN Jun, LI Ping, LIN Xiaohui, ZHANG Guoqian, ZHANG Shuxu. The expression and role of miR-17 in radioresistant cells of non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 391-397.
[3]	CAI Jing, HOU Yue. The expression and clinical significance of serum miR-195 in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 415-419.
[4]	CUI Xiaoyan,TU Qing,GAN Jianhui. Comparison between nalbuphine and oxycodone applied for patient controlled analgesia on postoperative immunological factor levels in patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 309-314.
[5]	LEI Junhua, XU Guanhua, ZENG Jiangzheng, HUANG Fen, HE Zhihui, LU Yanda. Research on JAK3/STAT3 mechanism of non-small cell lung cancer NCI-H1975 cells treated with cryptotanshinone combined with cisplatin [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 198-202.
[6]	ZHAI Keke, GAO Yuanyuan, FENG Xiao, XU Jingwen, GONG Yufang, MENG Qingwei. Analysis of first-line NSCLC chemotherapy in the phase Ⅳ patients with distant metastasis and first diagnosis after postoperative adjuvant chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 107-111.
[7]	DU Yesheng, HU Songliu, XU Xiangying. Study of oligodendrocyte metastasis in non-small cell lung cancer by stereotactic radiotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 154-158.
[8]	SUN Mingliang, XU Jianyu, XU Xiangying. Stereotactic radiotherapy for early stage of non - small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(1): 53-56.
[9]	DAI Xin, ZHANG Daxin. Current status of anti-angiogenesis therapy for non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(5): 472-476.
[10]	HU Haifeng,FENG Xiemin,QIAO Jian,DUAN Wei,LIU Ningning,SUN Xiaodong. The expression and clinical significance of miR-345 in non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 117-122.
[11]	ZHANG Rui,WANG Zhiyu,WANG Shuai,ZHAO Hui. Efficacy of recombinant human endostatin combined with vinorelbine-cisplatin regimen in newly diagnosed patients with advanced non-small cell lung cancer patients with bone metastases and the impact on expression of serum VEGF [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 527-522.
[12]	CUI Junpeng, LIU Baolin. Association between VDR gene FokI polymorphism and colorectal cancer susceptibility:a meta-analysis [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 400-408.
[13]	REN Fenghai,WANG Dandan,WANG Junfeng,XU Hai,XU Shidong. Clinical comparative study between Uniportal and single port video-assisted thoracoscopic surgery for ⅠA stage non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 327-331.
[14]	YAN Xiangyong ,YAN Zhongsheng ,LIU Wenchao ,DING Hui. Effect and safety of celiac continued circulatory hyperthermia perfusion with chemotherapy in the treatment of cancer with ascites Meta-analysis [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(4): 356-364.
[15]	YE Leiguang, YAN An, LIU Baogang. Relationship between Aurora-A mediated drug resistance and prognosis of patients with non-small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 97-102.

Maintenance therapy with pemetrexed for advanced non-small cell lung cancer:A Meta-analysis of RCTs

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments